» Articles » PMID: 36342324

Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a

Abstract

The continuous and rapid surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with high transmissibility and evading neutralization is alarming, necessitating expeditious detection of the variants concerned. Here, we report the development of rapid RS-CoV-2 ariants nzymatic etection (SAVED) based on CRISPR-Cas12a targeting of previously crucial variants, including Alpha, Beta, Gamma, Delta, Lambda, Mu, Kappa, and currently circulating variant of concern (VOC) Omicron and its subvariants BA.1, BA.2, BA.3, BA.4, and BA.5. SAVED is inexpensive (US$3.23 per reaction) and instrument-free. SAVED results can be read out by fluorescence reader and tube visualization under UV/blue light, and it is stable for 1 h, enabling high-throughput screening and point-of-care testing. We validated SAVED performance on clinical samples with 100% specificity in all samples and 100% sensitivity for the current pandemic Omicron variant samples having a threshold cycle () value of ≤34.9. We utilized chimeric CRISPR RNA (crRNA) and short crRNA (15-nucleotide [nt] to 17-nt spacer) to achieve single nucleotide polymorphism (SNP) genotyping, which is necessary for variant differentiation and is a challenge to accomplish using CRISPR-Cas12a technology. We propose a scheme that can be used for discriminating variants effortlessly and allows for modifications to incorporate newer upcoming variants as the mutation site of these variants may reappear in future variants. Rapid differentiation and detection tests that can directly identify SARS-CoV-2 variants must be developed in order to meet the demands of public health or clinical decisions. This will allow for the prompt treatment or isolation of infected people and the implementation of various quarantine measures for those exposed. We report the development of the rapid RS-CoV-2 ariants nzymatic etection (SAVED) method based on CRISPR-Cas12a that targets previously significant variants like Alpha, Beta, Gamma, Delta, Lambda, Mu, and Kappa as well as the VOC Omicron and its subvariants BA.1, BA.2, BA.3, BA.4, and BA.5 that are currently circulating. SAVED uses no sophisticated instruments and is reasonably priced ($3.23 per reaction). As the mutation location of these variations may reoccur in subsequent variants, we offer a system that can be applied for variant discrimination with ease and allows for adjustments to integrate newer incoming variants.

Citing Articles

Iterative crRNA design and a PAM-free strategy enabled an ultra-specific RPA-CRISPR/Cas12a detection platform.

Mao X, Xu J, Jiang J, Li Q, Yao P, Jiang J Commun Biol. 2024; 7(1):1454.

PMID: 39506042 PMC: 11541961. DOI: 10.1038/s42003-024-07173-7.


Early monitoring-to-warning Internet of Things system for emerging infectious diseases via networking of light-triggered point-of-care testing devices.

Fu Y, Liu Y, Song W, Yang D, Wu W, Lin J Exploration (Beijing). 2024; 3(6):20230028.

PMID: 38264687 PMC: 10742204. DOI: 10.1002/EXP.20230028.


New design strategies for ultra-specific CRISPR-Cas13a-based RNA detection with single-nucleotide mismatch sensitivity.

Molina Vargas A, Sinha S, Osborn R, Arantes P, Patel A, Dewhurst S Nucleic Acids Res. 2023; 52(2):921-939.

PMID: 38033324 PMC: 10810210. DOI: 10.1093/nar/gkad1132.


"Nano COVID-19": Nanopore sequencing of spike gene to identify SARS-CoV-2 variants of concern.

Nimsamer P, Sawaswong V, Klomkliew P, Kaewsapsak P, Puenpa J, Poovorawan Y Exp Biol Med (Maywood). 2023; 248(20):1841-1849.

PMID: 37702217 PMC: 10792430. DOI: 10.1177/15353702231190931.


[Rapid detection and genotyping of SARS-CoV-2 Omicron BA.4/5 variants using a RT-PCR and CRISPR-Cas12a-based assay].

Ma Y, Zou L, Liang Y, Liu Q, Sun Q, Pang Y Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(4):516-526.

PMID: 37202186 PMC: 10202775. DOI: 10.12122/j.issn.1673-4254.2023.04.03.